Tirdzniecība Cardiff Oncology, Inc. - CRDF CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.0228 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.025457% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.003235% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Cardiff Oncology Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 1.5586 |
| Atvērt* | 1.6085 |
| Izmaiņas par 1 gadu* | 34.04% |
| Dienas Diapazons* | 1.5486 - 1.6085 |
| 52 ned Diapazons | 1.20-3.41 |
| Vidējais apjoms (10 dienas) | 116.05K |
| Vidējais apjoms (3 mēneši) | 4.05M |
| Tirgus Kapitalizācija | 71.93M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 44.68M |
| Ieņēmumi | 395.00K |
| EPS | -0.89 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 1.75 |
| Nākamās Peļņas Datums | Aug 2, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Jun 1, 2023 | 1.5586 | -0.0300 | -1.89% | 1.5886 | 1.6185 | 1.5586 |
| May 31, 2023 | 1.5786 | 0.0000 | 0.00% | 1.5786 | 1.6185 | 1.5586 |
| May 30, 2023 | 1.5886 | -0.0999 | -5.92% | 1.6885 | 1.7184 | 1.5586 |
| May 26, 2023 | 1.6185 | 0.0300 | 1.89% | 1.5885 | 1.6685 | 1.5686 |
| May 25, 2023 | 1.6085 | -0.0600 | -3.60% | 1.6685 | 1.6785 | 1.5985 |
| May 24, 2023 | 1.6585 | -0.0100 | -0.60% | 1.6685 | 1.6985 | 1.6385 |
| May 23, 2023 | 1.7384 | 0.0699 | 4.19% | 1.6685 | 1.7584 | 1.6685 |
| May 22, 2023 | 1.6585 | -0.0400 | -2.36% | 1.6985 | 1.7185 | 1.6585 |
| May 19, 2023 | 1.6585 | -0.0599 | -3.49% | 1.7184 | 1.7184 | 1.6385 |
| May 18, 2023 | 1.6585 | -0.0699 | -4.04% | 1.7284 | 1.7684 | 1.6385 |
| May 17, 2023 | 1.7284 | 0.0799 | 4.85% | 1.6485 | 1.7584 | 1.6485 |
| May 16, 2023 | 1.6785 | -0.0200 | -1.18% | 1.6985 | 1.7285 | 1.6685 |
| May 15, 2023 | 1.7084 | -0.0400 | -2.29% | 1.7484 | 1.7884 | 1.6985 |
| May 12, 2023 | 1.6785 | -0.0100 | -0.59% | 1.6885 | 1.7284 | 1.6585 |
| May 11, 2023 | 1.6685 | -0.0499 | -2.90% | 1.7184 | 1.7285 | 1.6585 |
| May 10, 2023 | 1.6885 | -0.0699 | -3.98% | 1.7584 | 1.8184 | 1.6585 |
| May 9, 2023 | 1.7284 | 0.0000 | 0.00% | 1.7284 | 1.7684 | 1.6685 |
| May 8, 2023 | 1.7584 | -0.0899 | -4.86% | 1.8483 | 1.8483 | 1.7484 |
| May 5, 2023 | 1.8183 | -0.1100 | -5.70% | 1.9283 | 1.9283 | 1.7984 |
| May 4, 2023 | 1.8983 | 0.0899 | 4.97% | 1.8084 | 1.9882 | 1.8084 |
Cardiff Oncology, Inc. Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| Thursday, June 15, 2023 | ||
| Laiks (UTC) (UTC) 13:00 | Valsts US
| Notikums Cardiff Oncology Inc Annual Shareholders Meeting Cardiff Oncology Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 2, 2023 | ||
| Laiks (UTC) (UTC) 10:59 | Valsts US
| Notikums Q2 2023 Cardiff Oncology Inc Earnings Release Q2 2023 Cardiff Oncology Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Laiks (UTC) (UTC) 10:59 | Valsts US
| Notikums Q3 2023 Cardiff Oncology Inc Earnings Release Q3 2023 Cardiff Oncology Inc Earnings ReleaseForecast -Previous - |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0.386 | 0.359 | 0.36599 | 0.24463 | 0.37833 |
| Ienākumi | 0.386 | 0.359 | 0.36599 | 0.24463 | 0.37833 |
| Cost of Revenue, Total | 0 | 0.59746 | |||
| Bruto Peļņa | 0.24463 | -0.21913 | |||
| Kopējie Darbības Izdevumi | 40.288 | 29.214 | 19.4519 | 16.9231 | 17.4138 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 13.181 | 11.838 | 8.21647 | 5.76089 | 8.00558 |
| Pētniecība un Attīstība | 27.107 | 17.376 | 11.2354 | 11.1622 | 8.16401 |
| Neparedzēti Izdevumi (Ienākumi) | 0 | 0.64671 | |||
| Darbības Izdevumi | -39.902 | -28.855 | -19.0859 | -16.6785 | -17.0354 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 1.581 | 0.549 | -0.19256 | 0.26236 | 0.81109 |
| Citi, Neto | -0.383 | 0.015 | -0.02824 | 0.00198 | -0.23683 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -38.704 | -28.291 | -19.3067 | -16.4142 | -16.4612 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -38.704 | -28.291 | -19.3067 | -16.4142 | -16.4612 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -38.704 | -28.291 | -19.3067 | -16.4142 | -16.4612 |
| Neto Ienākumi | -38.704 | -28.291 | -19.3067 | -16.4142 | -16.4612 |
| Total Adjustments to Net Income | -0.024 | -0.024 | -3.29072 | -0.29251 | -2.79377 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -38.728 | -28.315 | -22.5974 | -16.7067 | -19.2549 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -38.728 | -28.315 | -22.5974 | -16.7067 | -19.2549 |
| Atšķaidīšanas Iestāstīšana | |||||
| Atšķaidītie Neto Ienākumi | -38.728 | -28.315 | -22.5974 | -16.7067 | -19.2549 |
| Atšķaidītie Ienākumi par Akcijām | 43.6 | 39.03 | 20.8747 | 5.97391 | 2.33018 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.88826 | -0.72547 | -1.08253 | -2.79661 | -8.26329 |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.88826 | -0.72547 | -1.08253 | -2.79661 | -7.98575 |
| Ārkārtas Posteņi Kopā |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 0.083 | 0.128 | 0.093 | 0.091 | 0.074 |
| Ienākumi | 0.083 | 0.128 | 0.093 | 0.091 | 0.074 |
| Kopējie Darbības Izdevumi | 12.135 | 9.52 | 9.086 | 10.534 | 11.148 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 3.083 | 3.078 | 3.077 | 3.086 | 3.94 |
| Pētniecība un Attīstība | 9.052 | 6.442 | 6.009 | 7.448 | 7.208 |
| Darbības Izdevumi | -12.052 | -9.392 | -8.993 | -10.443 | -11.074 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.94 | 0.74 | 0.458 | 0.253 | 0.13 |
| Citi, Neto | -0.111 | -0.045 | -0.036 | -0.253 | -0.049 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -11.223 | -8.697 | -8.571 | -10.443 | -10.993 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -11.223 | -8.697 | -8.571 | -10.443 | -10.993 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -11.223 | -8.697 | -8.571 | -10.443 | -10.993 |
| Neto Ienākumi | -11.223 | -8.697 | -8.571 | -10.443 | -10.993 |
| Total Adjustments to Net Income | -0.006 | -0.006 | -0.006 | -0.006 | -0.006 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -11.229 | -8.703 | -8.577 | -10.449 | -10.999 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -11.229 | -8.703 | -8.577 | -10.449 | -10.999 |
| Atšķaidītie Neto Ienākumi | -11.229 | -8.703 | -8.577 | -10.449 | -10.999 |
| Atšķaidītie Ienākumi par Akcijām | 44.677 | 44.527 | 43.333 | 43.306 | 43.231 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.25134 | -0.19545 | -0.19793 | -0.24128 | -0.25442 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.25134 | -0.19545 | -0.19793 | -0.24128 | -0.25442 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 111.284 | 146.127 | 133.356 | 11.3537 | 12.7653 |
| Nauda un Īstermiņa Ieguldījumi | 105.267 | 140.821 | 130.981 | 10.1953 | 11.4531 |
| Nauda un Ekvivalenti | 16.347 | 11.943 | 130.981 | 10.1953 | 11.4531 |
| Īstermiņa Ieguldījumi | 88.92 | 128.878 | |||
| Debitoru Parādu Kopsumma, Neto | 0.771 | 0.535 | 0.32046 | 0.20348 | 0.16776 |
| Accounts Receivable - Trade, Net | 0.771 | 0.535 | 0.32046 | 0.20348 | 0.16776 |
| Prepaid Expenses | 5.246 | 4.771 | 2.05532 | 0.95496 | 1.14438 |
| Total Assets | 116.191 | 149.544 | 134.727 | 13.0865 | 14.1725 |
| Property/Plant/Equipment, Total - Net | 3.52 | 3.178 | 0.9667 | 1.57524 | 1.30443 |
| Property/Plant/Equipment, Total - Gross | 6.933 | 6.619 | 3.97072 | 4.17953 | 3.41449 |
| Accumulated Depreciation, Total | -3.413 | -3.441 | -3.00403 | -2.60429 | -2.11006 |
| Other Long Term Assets, Total | 1.387 | 0.239 | 0.40423 | 0.15758 | 0.1028 |
| Total Current Liabilities | 7.808 | 6.559 | 6.11898 | 4.78174 | 2.92332 |
| Accounts Payable | 1.956 | 1.439 | 1.36601 | 0.6563 | 0.66484 |
| Accrued Expenses | 5.727 | 4.523 | 4.22897 | 3.69269 | 1.35082 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 0.125 | 0.597 | 0.524 | 0.43276 | 0.90766 |
| Total Liabilities | 9.848 | 9.127 | 6.56951 | 5.7752 | 4.0883 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Long Term Debt | |||||
| Other Liabilities, Total | 2.04 | 2.568 | 0.45053 | 0.99346 | 1.16499 |
| Total Equity | 106.343 | 140.417 | 128.158 | 7.31134 | 10.0842 |
| Redeemable Preferred Stock | 1.044 | 0.606 | 0.606 | 0.606 | 0.606 |
| Preferred Stock - Non Redeemable, Net | -1.044 | -0.605 | -0.60528 | -0.60594 | -0.60594 |
| Common Stock | 0.004 | 0.004 | 0.00368 | 0.00831 | 0.00774 |
| Additional Paid-In Capital | 404.834 | 400.503 | 361.82 | 217.173 | 202.268 |
| Retained Earnings (Accumulated Deficit) | -298.1 | -259.81 | -231.495 | -208.898 | -192.191 |
| Other Equity, Total | -0.395 | -0.281 | -2.17126 | -0.97167 | 0 |
| Total Liabilities & Shareholders’ Equity | 116.191 | 149.544 | 134.727 | 13.0865 | 14.1725 |
| Total Common Shares Outstanding | 44.677 | 41.964 | 36.7808 | 8.59363 | 3.83188 |
| Total Preferred Shares Outstanding | 0.0606 | 0.71564 | 0.0606 | 0.0606 | 0.0606 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 101.753 | 111.284 | 119.755 | 127.414 | 135.806 |
| Nauda un Īstermiņa Ieguldījumi | 96.968 | 105.267 | 114.303 | 122.006 | 129.362 |
| Nauda un Ekvivalenti | 15.017 | 16.347 | 18.717 | 20.965 | 20.052 |
| Īstermiņa Ieguldījumi | 81.951 | 88.92 | 95.586 | 101.041 | 109.31 |
| Debitoru Parādu Kopsumma, Neto | 0.676 | 0.771 | 0.65 | 0.551 | 0.447 |
| Accounts Receivable - Trade, Net | 0.676 | 0.771 | 0.65 | 0.551 | 0.447 |
| Prepaid Expenses | 4.109 | 5.246 | 4.802 | 4.857 | 5.997 |
| Total Assets | 106.549 | 116.191 | 123.631 | 131.261 | 139.204 |
| Property/Plant/Equipment, Total - Net | 3.435 | 3.52 | 3.692 | 3.662 | 3.21 |
| Property/Plant/Equipment, Total - Gross | 6.894 | 6.933 | 7.021 | 7.137 | 6.682 |
| Accumulated Depreciation, Total | -3.459 | -3.413 | -3.329 | -3.475 | -3.472 |
| Other Long Term Assets, Total | 1.361 | 1.387 | 0.184 | 0.185 | 0.188 |
| Total Current Liabilities | 8.148 | 7.808 | 8.245 | 8.481 | 6.664 |
| Accounts Payable | 2.914 | 1.956 | 1.425 | 1.522 | 1.261 |
| Accrued Expenses | 5.109 | 5.727 | 6.255 | 6.401 | 4.842 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.125 | 0.125 | 0.565 | 0.558 | 0.561 |
| Total Liabilities | 10.046 | 9.848 | 10.419 | 10.787 | 9.102 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 1.898 | 2.04 | 2.174 | 2.306 | 2.438 |
| Total Equity | 96.503 | 106.343 | 113.212 | 120.474 | 130.102 |
| Redeemable Preferred Stock | 1.05 | 1.044 | 0.606 | 0.606 | 0.606 |
| Common Stock | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Additional Paid-In Capital | 405.898 | 404.834 | 403.822 | 402.71 | 401.655 |
| Retained Earnings (Accumulated Deficit) | -309.323 | -298.1 | -289.835 | -281.258 | -270.809 |
| Other Equity, Total | -0.076 | -0.395 | -0.779 | -0.982 | -0.748 |
| Total Liabilities & Shareholders’ Equity | 106.549 | 116.191 | 123.631 | 131.261 | 139.204 |
| Total Common Shares Outstanding | 44.677 | 44.677 | 43.335 | 43.306 | 43.306 |
| Total Preferred Shares Outstanding | 0.0606 | 0.0606 | 0.38811 | 0.38811 | 0.38811 |
| Preferred Stock - Non Redeemable, Net | -1.05 | -1.044 | -0.606 | -0.606 | -0.606 |
- Ikgadējs
- Ceturkšņa
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -38.704 | -28.291 | -19.3067 | -16.4142 | -16.4612 |
| Nauda no Darbības | -33.82 | -23.04 | -16.315 | -13.2675 | -13.199 |
| Nauda no Darbības | 0.236 | 0.451 | 0.46601 | 0.49423 | 0.85949 |
| Bezskaidras Naudas Preces | 5.028 | 6.589 | 3.18023 | 1.56008 | 2.09003 |
| Cash Taxes Paid | 0.002 | 0.001 | 0.0008 | 0.0008 | 0.0008 |
| Samaksātie Procenti Naudā | 0 | 0.02248 | |||
| Izmaiņas Apgrozāmajā Kapitālā | -0.38 | -1.789 | -0.65453 | 1.09235 | 0.31265 |
| Nauda no Ieguldījumu Darbībām | 38.149 | -131.448 | -0.21188 | -0.06762 | 0.02284 |
| Kapitālie Izdevumi | -1.006 | -0.205 | -0.21188 | -0.06762 | -0.0051 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 39.155 | -131.243 | 0 | 0.02794 | |
| Nauda no Darbībām ar Finansēšanu | 0.075 | 35.45 | 137.312 | 12.0773 | 16.4035 |
| Akciju Izsniegšana (Atkāpšanās), Neto | 0.075 | 35.45 | 137.32 | 12.1173 | 19.6127 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 0 | 0 | 0 | -1.37541 | |
| Ārvalstu Valūtas Ietekme | 0 | ||||
| Neto Izmaiņas Naudā | 4.404 | -119.038 | 120.785 | -1.25784 | 3.22737 |
| Naudas Plūsma Finansēšanas Posteņos | 0 | -0.0075 | -0.04 | -1.83374 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -11.223 | -38.704 | -30.007 | -21.436 | -10.993 |
| Cash From Operating Activities | -8.659 | -33.82 | -24.43 | -16.944 | -10.249 |
| Cash From Operating Activities | 0.09 | 0.236 | 0.15 | 0.069 | 0.031 |
| Non-Cash Items | 0.901 | 5.028 | 4.055 | 2.903 | 1.637 |
| Cash Taxes Paid | 0 | 0.002 | 0.001 | 0.001 | 0.001 |
| Changes in Working Capital | 1.573 | -0.38 | 1.372 | 1.52 | -0.924 |
| Cash From Investing Activities | 7.329 | 38.149 | 31.129 | 25.966 | 18.358 |
| Other Investing Cash Flow Items, Total | 7.337 | 39.155 | 32.06 | 26.449 | 18.529 |
| Cash From Financing Activities | 0 | 0.075 | 0.075 | 0 | 0 |
| Issuance (Retirement) of Stock, Net | 0.075 | 0.075 | 0 | 0 | |
| Net Change in Cash | -1.33 | 4.404 | 6.774 | 9.022 | 8.109 |
| Financing Cash Flow Items | 0 | ||||
| Issuance (Retirement) of Debt, Net | |||||
| Capital Expenditures | -0.008 | -1.006 | -0.931 | -0.483 | -0.171 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| Pfizer Inc | Corporation | 5.3978 | 2411575 | 0 | 2023-04-24 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.3488 | 1942918 | 0 | 2023-03-31 | LOW |
| Acorn Bioventures L.P. | Venture Capital | 2.9803 | 1331507 | 0 | 2022-12-31 | MED |
| Caxton Associates LP | Hedge Fund | 2.2016 | 983607 | 983607 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.6795 | 750359 | 7972 | 2023-03-31 | LOW |
| Laurion Capital Management LP | Hedge Fund | 1.6163 | 722100 | 0 | 2023-03-31 | HIGH |
| Citi Investment Research (US) | Research Firm | 1.4575 | 651161 | 651061 | 2023-03-31 | LOW |
| Pace (Gary William) | Individual Investor | 1.4433 | 644811 | 0 | 2023-04-24 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9255 | 413502 | 0 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 0.8841 | 394994 | 215451 | 2023-03-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.7416 | 331308 | -159682 | 2023-03-31 | HIGH |
| GSA Capital Partners LLP | Hedge Fund | 0.6282 | 280679 | -71507 | 2023-03-31 | LOW |
| Susquehanna International Group, LLP | Investment Advisor | 0.4309 | 192503 | 10122 | 2023-03-31 | MED |
| Morgan Stanley & Co. LLC | Research Firm | 0.4297 | 191963 | -76155 | 2023-03-31 | MED |
| Two Sigma Investments, LP | Hedge Fund | 0.3883 | 173500 | -36709 | 2023-03-31 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.3132 | 139945 | 0 | 2023-03-31 | LOW |
| William Blair & Company, L.L.C. (Research) | Research Firm | 0.2921 | 130500 | -21075 | 2023-03-31 | LOW |
| ACT Capital Management, L.L.C. | Hedge Fund | 0.2699 | 120600 | 0 | 2022-09-30 | MED |
| White (Lale) | Individual Investor | 0.2547 | 113788 | 43858 | 2023-04-24 | |
| Abaris Investment Management AG | Investment Advisor | 0.2364 | 105600 | 0 | 2022-10-31 | MED |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group535K+
Tirgotāji
87K+
Ikmēneša aktīvie klienti
$113M+
Ikmēneša ieguldījumu apjoms
$64M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
Cardiff Oncology, Inc. Company profile
Par Cardiff Oncology, Inc.
Cardiff Oncology Inc. ir klīniskās stadijas biotehnoloģiju uzņēmums. Uzņēmums koncentrējas uz vēža pacientu ārstēšanas izstrādi. Tās zāļu kandidāts onvansertibs ir polo līdzīgas kināzes 1 (PLK1) adenozīna trifosfāta (ATP) konkurētspējīgs inhibitors, kas ir ķīmijterapijas un mērķterapijas kombinācija. Tās klīniskie pētījumi ietver TROV-054, CRDF-001 un TROV-053. TROV-054 ir I fāzes b/2 atklāts klīnisks pētījums ar onvansertibu kombinācijā ar FOLFIRI (folīnskābi, fluoruracilu un irinotekānu) un Avastin (bevacizumabu). TROV-053 ir II fāzes atklāts klīnisks pētījums par onvansertibu kombinācijā ar Zytiga (abiraterona acetātu)/prednizonu. CRDF-001 ir 2. fāzes atklāts daudzcentru klīnisks pētījums ar onvansertibu kombinācijā ar nanoliposomālu irinotekānu, leikovorīnu un fluorouracilu, lai otrajā līnijā ārstētu pacientus ar metastātisku aizkuņģa dziedzera duktālu adenokarcinomu (mPDAC).
| Industry: | Biotechnology & Medical Research (NEC) |
11055 Flintkote Ave
SAN DIEGO
CALIFORNIA 92121
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 535 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com